ABBV

Bristol Myers Squibb (BMY) is recommended over AbbVie (ABBV) despite ABBV's stronger revenue and earnings growth. BMY trades at a significant valuation discount (9.68X vs 18.21X forward earnings), offers a higher dividend yield (4% vs 2.43%), and has a better Zacks Rank (#3 Hold vs #4 Sell). However, BMY faces challenges from legacy drug erosion and elevated debt levels, while ABBV benefits from strong Skyrizi and Rinvoq growth but faces intensifying competition and downward earnings revisions.

AbbVie is expected to report Q3 2026 earnings of $3.79 per share (up 103.8% YoY) with revenues of $17.37 billion (up 10.1% YoY) on October 30. However, the stock carries a Zacks Rank #4 with a negative Earnings ESP of -0.26%, making it difficult to predict an earnings beat. The company has beaten consensus estimates in four consecutive quarters.

With the Federal Reserve likely to maintain or raise interest rates through the end of 2026, dividend stocks like AbbVie are positioned to perform well. AbbVie, a pharmaceutical company with over 50 years of dividend increases, offers resilience in a high-rate environment due to its strong balance sheet, fixed-rate debt, and non-rate-sensitive business model.

AbbVie's neuroscience revenues are projected to reach $3.29 billion in Q3 2026, representing approximately 16% year-over-year growth. Key contributors include established drugs Vraylar ($1.08B) and Botox Therapeutic ($1.07B), along with newer products like Vyalev ($283M) and the recently FDA-approved Juvmo. The company faces competition from Biogen and Johnson & Johnson in the neuroscience market.

Zacks Market Edge podcast episode #503 features five stock picks for investors seeking opportunities amid market volatility. The selections span growth stocks (Palantir, Palo Alto Networks), value plays (BP), consistent performers (Visa), and pharmaceuticals (AbbVie), offering diverse investment strategies across different market conditions.

Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments.

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

AbbVie is positioned as a reliable dividend stock that avoids high-yield trap characteristics. With 54 consecutive years of dividend increases, strong free cash flow generation, fixed-rate debt, and blockbuster drugs Skyrizi and Rinvoq generating over $7.5 billion quarterly, AbbVie maintains Dividend King status regardless of interest rate cycles. The company's robust pipeline of 90 clinical programs provides future revenue stability.

AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer.

Zacks stock strategist Tracey Ryniec highlights five stocks breaking out to new highs despite October market volatility. The picks span growth and value categories: Palantir Technologies (strong revenue growth but expensive valuation), BP (cheap energy play with high dividend yield), Palo Alto Networks (cybersecurity leader with consistent earnings), Visa (payments leader with perfect earnings track record), and AbbVie (pharma company with growth potential but recent estimate cuts).

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook.

AbbVie has recently attracted investor attention with shares returning +4.3% over the past month, outperforming the S&P 500's +2.1% gain. However, despite strong earnings growth expectations (+104.3% YoY for current quarter) and consistent beats on both EPS and revenue estimates, the company received a Zacks Rank #4 (Sell) rating due to recent downward revisions in consensus earnings estimates. The stock is valued at par with peers (C grade) but may underperform the broader market in the near term.

AbbVie (ABBV) rose 1.65% to $281.04, outperforming the S&P 500's decline. The stock has gained 7.53% over the past month and is expected to report earnings on October 30, 2026, with projected EPS growth of 104.3% and revenue growth of 10.01%. However, the company carries a Zacks Rank #4 (Sell) rating, trades at a premium Forward P/E of 19.77 versus its industry average of 16.16, and consensus EPS estimates have declined 0.79% over the last 30 days.

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.

AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline.

AbbVie and Genmab announced positive phase III EPCORE DLBCL-2 study results showing that epcoritamab combined with R-CHOP significantly improved progression-free survival compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients, reducing disease progression or death risk by 51%. The combination was well tolerated with a safety profile consistent with prior reports.

AbbVie (ABBV) closed at $265.85, outperforming the S&P 500 with a +1.15% daily gain. The pharmaceutical company is expected to report earnings of $3.85 per share on October 30, 2026, representing 106.99% year-over-year growth, with revenue projected at $17.36 billion. AbbVie currently holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 18.71, trading at a premium to its industry average.

Despite recent Fed rate hikes and rising Treasury yields, the article recommends two blue chip dividend stocks: AbbVie, a Dividend King with 53 consecutive years of dividend increases and strong growth prospects from new drugs, and Medtronic, which is on track to become a Dividend King with 49 consecutive years of dividend hikes and improving operational performance after recent restructuring.